{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:52:37Z","timestamp":1783385557206,"version":"3.54.6"},"reference-count":33,"publisher":"Pharmaceutical Society of Japan","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2016]]},"DOI":"10.1248\/bpb.b16-00581","type":"journal-article","created":{"date-parts":[[2016,11,30]],"date-time":"2016-11-30T17:15:11Z","timestamp":1480526111000},"page":"2052-2059","source":"Crossref","is-referenced-by-count":32,"title":["Inhibitory Effect of Hesperetin and Naringenin on Human UDP-Glucuronosyltransferase Enzymes: Implications for Herb\u2013Drug Interactions"],"prefix":"10.1248","volume":"39","author":[{"given":"Dan","family":"Liu","sequence":"first","affiliation":[{"name":"Clinical Pharmacology Institute, Nanchang University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wu","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Institute, Nanchang University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Xie","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Institute, Nanchang University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyi","family":"Liu","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Institute, Nanchang University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaiah","family":"Takau","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Institute, Nanchang University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Institute, Nanchang University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Xiong","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Institute, Nanchang University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhua","family":"Xia","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Institute, Nanchang University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Krogholm KS, Bredsdorff L, Knuthsen P, Haraldsd\u00f3ttir J, Rasmussen SE. Relative bioavailability of the flavonoids quercetin, hesperetin and naringenin given simultaneously through diet. <i>Eur. J. Clin. Nutr.<\/i>, <b>64<\/b>, 432\u2013435 (2010).","DOI":"10.1038\/ejcn.2010.6"},{"key":"2","unstructured":"2) Yan Chen. Wang Jin yan, Jia Xiao bin, Xin Ran, Tan Xiao bin. Advances in studies on absorption, metabolism, and drug interaction of dihydrof lavones in <i>Aurantii Fructus Immaturus<\/i>. <i>Chin. Tradit. Herbal Drugs<\/i>, <b>41<\/b>, 1564\u20131566 (2010)."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Bredsdorff L, Nielsen ILF, Rasmussen SE, Cornett C, Barron D, Bouisset F, Offord E, Williamson G. Absorption, conjugation and excretion of the flavanones, naringenin and hesperetin from \u03b1-rhamnosidase-treated orange juice in human subjects. <i>Br. J. Nutr.<\/i>, <b>103<\/b>, 1602\u20131609 (2010).","DOI":"10.1017\/S0007114509993679"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Pingili R, Vemulapalli S, Mullapudi SS, Nuthakki S, Pendyala S, Kilaru N. Pharmacokinetic interaction study between flavanones (hesperetin, naringenin) and rasagiline mesylate in wistar rats. <i>Drug Dev. Ind. Pharm.<\/i>, <b>2015<\/b>, 1\u201333 (2015).","DOI":"10.3109\/03639045.2015.1115868"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Choi EJ, Ahn WS. Neuroprotective effects of chronic hesperetin administration in mice. <i>Arch. Pharm. Res.<\/i>, <b>31<\/b>, 1457\u20131462 (2008).","DOI":"10.1007\/s12272-001-2130-1"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Olsen HT, Stafford GI, van Staden J, Christensen SB, J\u00e4ger AK. Isolation of the MAO inhibitor naringenin from Mentha aquatica L. <i>J. Ethnopharmacol.<\/i>, <b>117<\/b>, 500\u2013502 (2008).","DOI":"10.1016\/j.jep.2008.02.015"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Ribeiro IA, Rocha J, Sepodes B, Mota-Filipe H, Ribeiro MH. Effect of naringin enzymatic hydrolysis towards naringenin on the anti-inflammatory activity of both compounds. <i>J. Mol. Catal., B Enzym.<\/i>, <b>52-53<\/b>, 13\u201318 (2008).","DOI":"10.1016\/j.molcatb.2007.10.011"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Bacanli M, Basaran AA, Basaran N. The antioxidant and antigenotoxic properties of citrus phenolics limonene and naringin. <i>Food Chem. Toxicol.<\/i>, <b>81<\/b>, 160\u2013170 (2015).","DOI":"10.1016\/j.fct.2015.04.015"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Ma HY, Sun DX, Cao YF, Ai CZ, Qu YQ, Hu CM, Jiang C, Dong PP, Sun XY, Hong M, Tanaka N, Gonzalez FJ, Ma XC, Fang ZZ. Herb\u2013drug interaction prediction based on the high specific inhibition of andrographolide derivatives towards UDP-glucuronosyltransferase (UGT) 2B7. <i>Toxicol. Appl. Pharmacol.<\/i>, <b>277<\/b>, 86\u201394 (2014).","DOI":"10.1016\/j.taap.2014.02.021"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, Ball SE. Drug\u2013drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (<i>AUC<\/i><sub>i<\/sub>\/<i>AUC<\/i>) ratios. <i>Drug Metab. Dispos.<\/i>, <b>32<\/b>, 1201\u20131208 (2004).","DOI":"10.1124\/dmd.104.000794"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Kiang TKL, Ensom MHH, Chang TKH. UDP-glucuronosyltransferases and clinical drug\u2013drug interactions. <i>Pharmacol. Ther.<\/i>, <b>106<\/b>, 97\u2013132 (2005).","DOI":"10.1016\/j.pharmthera.2004.10.013"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. <i>Science<\/i>, <b>286<\/b>, 487\u2013491 (1999).","DOI":"10.1126\/science.286.5439.487"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Williams JA, Ring BJ, Cantrell VE, Campanale K, Jones DR, Hall SD, Wrighton SA. Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes. <i>Drug Metab. Dispos.<\/i>, <b>30<\/b>, 1266\u20131273 (2002).","DOI":"10.1124\/dmd.30.11.1266"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Liu X, Huang T, Chen JX, Zeng J, Fan XR, Xu-Zhu, Yu ZW, Sun XY, Hong M, Sun HZ. Arbidol exhibits strong inhibition towards UDP-glucuronosyltransferase (UGT) 1A9 and 2B7. <i>Pharmazie<\/i>, <b>68<\/b>, 945\u2013950 (2013).","DOI":"10.1002\/ptr.4875"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Peer CJ, Sissung TM, Kim A, Jain L, Woo S, Gardner ER, Kirkland CT, Troutman SM, English BC, Richardson ED, Federspiel J, Venzon D, Dahut W, Kohn E, Kummar S, Yarchoan R, Giaccone G, Widemann B, Figg WD. Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. <i>Clin. Cancer Res.<\/i>, <b>18<\/b>, 2099\u20132107 (2012).","DOI":"10.1158\/1078-0432.CCR-11-2484"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Fang ZZ, Cao YF, Hu CM, Hong M, Sun XY, Ge GB, Liu Y, Zhang YY, Yang L, Sun HZ. Structure\u2013inhibition relationship of ginsenosides towards UDP-glucuronosyltransferases (UGTs). <i>Toxicol. Appl. Pharmacol.<\/i>, <b>267<\/b>, 149\u2013154 (2013).","DOI":"10.1016\/j.taap.2012.12.019"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Quintieri L, Bortolozzo S, Stragliotto S, Moro S, Pavanetto M, Nassi A, Palatini P, Floreani M. Flavonoids diosmetin and hesperetin are potent inhibitors of cytochrome P450 2C9-mediated drug metabolism <i>in vitro.<\/i> <i>Drug Metab. Pharmacokinet.<\/i>, <b>25<\/b>, 466\u2013476 (2010).","DOI":"10.2133\/dmpk.DMPK-10-RG-044"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Lu WJ, Ferlito V, Xu C, Flockhart DA, Caccamese S. Enantiomers of naringenin as pleiotropic, stereoselective inhibitors of cytochrome P450 isoforms. <i>Chirality<\/i>, <b>23<\/b>, 891\u2013896 (2011).","DOI":"10.1002\/chir.21005"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Zhu L, Ge G, Liu Y, He G, Liang S, Fang Z, Dong P, Cao Y, Yang L. Potent and selective inhibition of magnolol on catalytic activities of UGT1A7 and 1A9. <i>Xenobiotica<\/i>, <b>42<\/b>, 1001\u20131008 (2012).","DOI":"10.3109\/00498254.2012.681814"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Uchaipichat V, Mackenzie PI, Guo XH, Gardner-Stephen D, Galetin A, Houston JB, Miners JO. Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. <i>Drug Metab. Dispos.<\/i>, <b>32<\/b>, 413\u2013423 (2004).","DOI":"10.1124\/dmd.32.4.413"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Uchaipichat V, Mackenzie PI, Elliot DJ, Miners JO. Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) \u201cprobes\u201d for human UDPglucuronosyltransferases. <i>Drug Metab. Dispos.<\/i>, <b>34<\/b>, 449\u2013456 (2006).","DOI":"10.1124\/dmd.105.007369"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Zhou J, Tracy TS, Remmel RP. Glucuronidation of dihydrotestosterone and <i>trans<\/i>-androsterone by recombinant UDP-glucuronosyltransferase (UGT) 1A4: evidence for multiple UGT1A4 aglycone binding sites. <i>Drug Metab. Dispos.<\/i>, <b>38<\/b>, 431\u2013440 (2010).","DOI":"10.1124\/dmd.109.028712"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Fang ZZ, Wang H, Cao YF, Sun DX, Wang LX, Hong M, Huang T, Chen JX, Zeng J. Enantioselective Inhibition of Carprofen towards UDP-glucuronosyltransferase (UGT) 2B7. <i>Chirality<\/i>, <b>27<\/b>, 189\u2013193 (2014).","DOI":"10.1002\/chir.22412"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Ai LM, Zhu LL, Yang L, Ge GB, Cao Y, Liu Y, Fang Z, Zhang Y. Selectivity for inhibition of nilotinib on the catalytic activity of human UDP-glucuronosyltransferases. <i>Xenobiotica<\/i>, <b>44<\/b>, 320\u2013325 (2014).","DOI":"10.3109\/00498254.2013.840750"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Yu L, Lu S, Lin Y, Zeng S. Carboxyl-glucuronidation of mitiglinide by human UDP-glucuronosyltransferases. <i>Biochem. Pharmacol.<\/i>, <b>73<\/b>, 1842\u20131851 (2007).","DOI":"10.1016\/j.bcp.2007.02.004"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Lankisch TO, Gillman TC, Erichsen TJ, Ehmer U, Kalthoff S, Freiberg N, Munzel PA, Manns MP, Strassburg CP. Aryl hydrocarbon receptor-mediated regulation of the human estrogen and bile acid UDP-glucuronosyltransferase 1A3 gene. <i>Arch. Toxicol.<\/i>, <b>82<\/b>, 573\u2013582 (2008).","DOI":"10.1007\/s00204-008-0347-1"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Gall WE, Zawada G, Mojarrabi B, Tephly TR, Green MD, Coffman BL, Mackenzie PI, Radominska-Pandya A. Differential glucuronidation of bile acids, androgens and estrogens by human UGT1A3 and 2B7. <i>J. Steroid Biochem. Mol. Biol.<\/i>, <b>70<\/b>, 101\u2013108 (1999).","DOI":"10.1016\/S0960-0760(99)00088-6"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Liu X, Huang T, Chen JX, Zeng J, Fan XR, Xu-Zhu, Yu ZW, Sun XY, Hong M, Sun HZ. Arbidol exhibits strong inhibition towards UDP-glucuronosyltransferase (UGT) 1A9 and 2B7. <i>Pharmazie<\/i>, <b>68<\/b>, 945\u2013950 (2013).","DOI":"10.1002\/ptr.4875"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Ma HY, Sun DX, Cao YF, Ai CZ, Qu YQ, Hu CM, Jiang C, Dong PP, Sun XY, Hong M, Tanaka N, Gonzalez FJ, Ma XC, Fang ZZ. Herb-drug interaction prediction based on the high specific inhibition of andrographolide derivatives towards UDP-glucuronosyltransferase (UGT) 2B7. <i>Toxicol. Appl. Pharmacol.<\/i>, <b>277<\/b>, 86\u201394 (2014).","DOI":"10.1016\/j.taap.2014.02.021"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Fang Z-Z, Cao Y-F, Hu C-M, Hong M, Sun XY, Ge GB, Liu Y, Zhang YY, Yang L, Sun HZ. Structure\u2013inhibition relationship of ginsenosides towards UDP-glucuronosyltransferases (UGTs). <i>Toxicol. Appl. Pharmacol.<\/i>, <b>267<\/b>, 149\u2013154 (2013).","DOI":"10.1016\/j.taap.2012.12.019"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Dong RH, Fang ZZ, Zhu LL, Liang SC, Ge GB, Yang L, Liu ZY. Investigation of UDP-glucuronosyltransferases (UGT) inhibitory properties of carvacrol. <i>Phytother. Res.<\/i>, <b>26<\/b>, 86\u201390 (2012).","DOI":"10.1002\/ptr.3525"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Fang ZZ, Zhang YY, Wang XL, Cao YF, Huo H, Yang L. Bioactivation of herbal constituents: simple alerts in the complex system. <i>Expert Opin. Drug Metab. Toxicol.<\/i>, <b>7<\/b>, 989\u20131007 (2011).","DOI":"10.1517\/17425255.2011.586335"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Erlund I, Meririnne E, Alfthan G, Aro A. Plasma kinetics and urinary excretion of the flavanones naringenin and hesperetin in humans after ingestion of orange juice and grapefruit juice. <i>J. Nutr.<\/i>, <b>131<\/b>, 235\u2013241 (2001).","DOI":"10.1093\/jn\/131.2.235"}],"container-title":["Biological &amp; Pharmaceutical Bulletin","Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/39\/12\/39_b16-00581\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T23:57:18Z","timestamp":1568591838000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/39\/12\/39_b16-00581\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b16-00581","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}